Sir-Spheres Selective Radiation Therapy Approvable For Liver Cancer - Panel
This article was originally published in The Gray Sheet
Executive Summary
Sirtex Medical's Sir-Spheres embolic radiation therapy device for liver cancer is beneficial over traditional chemotherapy - despite the lack of a statistically insignificant increase in patient survival - because it offers a slower time to disease progression, FDA advisory panel members agreed at a Nov. 6 meeting in Rockville, Maryland.
You may also be interested in...
SingHealth, Aussie Sirtex Ink Research Collaboration For mAb-delivering Nanoparticles
SingHealth’s National Cancer Center has signed a research pact with Australia-listed oncology company Sirtex to begin preclinical work on a novel biologic targeted cancer therapy to determine if the method shows efficacy in removing microscopic “tumor islands” left after surgery.
SIRTeX SIR-Spheres PMA Supplement Submission Expected By Year-End
SIRTeX Medical is looking to follow its March 5 SIR-Spheres PMA approval for localized treatment of unresectable metastatic liver tumors with a PMA supplement submission by the end of the year for a systemic indication
SIRTeX SIR-Spheres PMA Supplement Submission Expected By Year-End
SIRTeX Medical is looking to follow its March 5 SIR-Spheres PMA approval for localized treatment of unresectable metastatic liver tumors with a PMA supplement submission by the end of the year for a systemic indication